Abstract: The present invention provides crystals of a quaternary ammonium salt structure compound, i.e., (2R,3R)-3-[(2-cyclopentyl-2-hydroxy-2-phenyl)ethoxy]-1-(3-phenoxypropyl) azabicyclo[2,2,2]octylonium bromide (Compound I). A Type-A crystal of Compound I displays diffraction peaks at the following diffraction angles 2? in a X-ray powder diffraction pattern thereof: 5.7±0.2 degrees, 12.9±0.2 degrees, 16.7±0.2 degrees, 18.0±0.2 degrees, 19.5±0.2 degrees, 21.1±0.2 degrees, 22.3±0.2 degrees and 23.3±0.2 degrees. A Type-B crystal of Compound I displays diffraction peaks at the following diffraction angles 2? in a X-ray powder diffraction pattern thereof: 5.2±0.2 degrees, 15.8±0.2 degrees, 16.9±0.2 degrees, 17.7±0.2 degrees, 19.5±0.2 degrees, 20.2±0.2 degrees and 22.1±0.2 degrees. The present application also relates to a new method for preparing Compound I and applications of the two novel crystals in the field of medicine.

Abstract: Provided is 2-(4-diethylamino)butylmalonic acid-(1R,2R)-(?)-1,2-cyclohexanediamine platinum(II) phosphate having high solubility, low hygroscopicity, and high stability and being suitable for preparing into various antitumor drug preparations. Also provided is a preparation method for amorphous 2-(4-diethylamino)butylmalonic acid-(1R,2R-)-1,2-cyclohexanediamine platinum(II) phosphate. The method is simple to operate and is suitable for industrial implementation.

Abstract: The invention provides a class of compounds represented by formula (I), having bifunctional active quaternary ammonium salt structure of a ?2-adrenoreceptor agonist and an M receptor antagonist, a pharmaceutically acceptable salt, solvate, and optical isomer thereof. A pharmaceutical composition comprising such a compound with quaternary ammonium salt structure, a method for preparing such a compound with quaternary ammonium salt structure and an intermediate thereof, and uses thereof in treating pulmonary disorders are also provided. The compounds of the invention have high selectivity to the M receptor subtype, and have less adverse reaction and lower toxic and side effects in the treatment of pulmonary diseases such as COPD and asthma.

Abstract: The invention provides a class of compounds represented by formula (I), having bifunctional active quaternary ammonium salt structure of a ?2-adrenoreceptor agonist and an M receptor antagonist, a pharmaceutically acceptable salt, solvate, and optical isomer thereof. A pharmaceutical composition comprising such a compound with quaternary ammonium salt structure, a method for preparing such a compound with quaternary ammonium salt structure and an intermediate thereof, and uses thereof in treating pulmonary disorders are also provided. The compounds of the invention have high selectivity to the M receptor subtype, and have less adverse reaction and lower toxic and side effects in the treatment of pulmonary diseases such as COPD and asthma.